Initial report from the Hunter Outcome Survey

Genetics in Medicine

Volumn 10, Issue 7, 2008, Pages 508-516

  Wraith, J Edmond ^a   Beck, Michael ^b   Giugliani, Roberto ^c   Clarke, Joe ^d,e   Martin, Rick ^f   Muenzer, Joseph ^g  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Hunter syndrome; Lysosomal storage disease; Mucopolysaccharidosis II

Indexed keywords

ABDOMINAL WALL HERNIA; ADOLESCENT; ARTICLE; AUDIOMETRY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FEMALE; HEALTH SURVEY; HEPATOSPLENOMEGALY; HUMAN; HUNTER SYNDROME; JOINT MOBILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; OTITIS MEDIA; OUTCOME ASSESSMENT; VITAL SIGN; CROSS-SECTIONAL STUDY; GENETICS; MORPHOMETRICS; MUTATION; PATHOLOGY; PHENOTYPE; PREVALENCE; TREATMENT OUTCOME;

GLYCOPROTEIN; IDS PROTEIN, HUMAN;

BODY WEIGHTS AND MEASURES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS II; MUTATION; PHENOTYPE; PREVALENCE; TREATMENT OUTCOME;

EID: 52049124506     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31817701e6     Document Type: Article

References (43)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: 3421-3452.
2. Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A 1973;70: 2134-2138.
3. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-1017.
4. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254.
5. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-156.
6. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997;101:355-358.
7. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet 2003;123:310-313.
8. Lowry RB, Renwick DH. Relative frequency of the Hurler and Hunter syndromes. N Engl J Med 1971;284:221-222.
9. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:e10.
10. Wilson PJ, Suthers GK, Callen DF, et al. Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum Genet 1991;86:505-508.
11. Kim CH, Hwang HZ, Song SM, et al. Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations. Hum Mutat 2003;21:449-450.
12. Lissens W, Seneca S, Liebaers I. Molecular analysis in 23 Hunter disease families. J Inherit Metab Dis 1997;20:453-456.
13. Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 1998;79:237-241.
14. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983;25:481-489.
15. Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child 1982;57:828-836.
16. Martin R, Beck M, Giugliani R, Harmatz P, Munoz MV, Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121: e377-e386.
17. Coppa GV, Gabrielli O, Zampini L, et al. Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two year follow-up of the first Italian patient and review of the literature. Ped Med Chir 1995;17:227-235.
18. McKinnis EJ, Sulzbacher S, Rutledge JC, Sanders J, Sanders J, Scott CR. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996;129:145-148.
19. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-648.
20. Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant 2000;25:1097-1099.
21. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473.
22. Young ID, Harper PS. Psychosocial problems in Hunter's syndrome. Child Care Health Dev 1981;7:201-209.
23. Schwartz IV, Ribeiro MG, Mota JG, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2007;96:63-70.
24. Young ID, Harper PS. Long-term complications in Hunter's syndrome. Clin Genet 1979;16:125-132.
25. Morehead JM, Parsons DS. Tracheobronchomalacia in Hunter's syndrome. Int J Pediatr Otorhinolaryngol 1993;26:255-261.
26. Benson PF, Button LR, Fensom AH, Dean MF. Lumbar kyphosis in Hunter's disease (MPS II). Clin Genet 1979;16:317-322.
27. Brama I, Gay I, Feinmesser R, Springer C. Upper airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 1986;11:229-235.
28. National High Blood Pressure Education Program. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-576.
29. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 2002;11:1-190.
30. Nellhaus G. Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics 1968;41:106-114.
31. Hunter C. A rare disease in two brothers. Proc R Soc Med 1917;10:104-116.
32. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2571.
33. Who Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl 2006;450:86-95.
34. Schum TR, Kolb TM, McAuliffe TL, Simms MD, Underhill RL, Lewis M. Sequential acquisition of toilet-training skills: a descriptive study of gender and age differences in normal children. Pediatrics 2002;109:E48.
35. Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006;66:77-84.
36. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-1235.
37. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192.
38. Pastores GM, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type 1. Mol Genet Metab 2007;91:37-47.
39. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-608.
40. Sobreira E, Pires RF, Cizmarik M, Grabowski GA. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest-of-the-world. Mol Genet Metab 2007;90:81-86.
41. Weinreb NJ, Aggio MC, Andersson HC, Andria G, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41:15-22.
42. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007;22:119-126.
43. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007;71:205-211.